Background Gastrin-releasing peptide receptor antagonists have promise in theranostics of
several highly incident tumours, including prostate and breast. This study presents the first …

Context Tumor-induced osteomalacia (TIO) is a paraneoplastic disorder, usually caused by
benign mesenchymal tumors that produce high levels of fibroblast growth factor 23. The only …

Hepatocellular carcinoma is the most common primary liver cancer and the fifth most
frequently diagnosed cancer worldwide. Most patients with advanced disease are offered …

Background Actinium-225 is an alpha-particle emitter under investigation for use in
radiopharmaceutical therapy. To address limited supply, accelerator-produced 225 Ac has …

Purpose We have determined the in vivo relative biological effectiveness (RBE) of an alpha-
particle–emitting radiopharmaceutical therapeutic agent (212 Pb-labeled anti-HER2/neu …

Because of the concerns associated with radiation exposure at a young age, there is an
increased interest in pediatric absorbed dose estimates for imaging agents. Almost all …

Radiopharmaceutical dosimetry is an important area of nuclear medicine, and its advances
have the potential to affect imaging and radiotherapy development and application …

Background Dosimetry for diagnostic agents is performed to assess the risk of radiation
detriment (eg, cancer) associated with the imaging agent and the risk is assessed by …

Targeted radiopharmaceutical therapy (TRT) involving systemic administration of a tumor-
selective agent labeled with a radionuclide has demonstrated considerable promise for …

The use of radionuclides in the treatment of benign and malignant diseases began with the
discovery of radioactivity in the early 1900s. Radium was first used in the local treatment of …